Seek Returns logo

RGC vs. TEVA: A Head-to-Head Stock Comparison

Updated on

Here’s a clear look at RGC and TEVA, comparing key factors like historical performance, profitability, financial strength, growth, dividend, and valuation.

Company Profile

RGC is a standard domestic listing, while TEVA trades as an American Depositary Receipt (ADR), offering U.S. investors access to its foreign-listed shares.

SymbolRGCTEVA
Company NameRegencell Bioscience Holdings LimitedTeva Pharmaceutical Industries Limited
CountryHong KongIsrael
GICS SectorHealth CareHealth Care
GICS IndustryPharmaceuticalsPharmaceuticals
Market Capitalization6.10 billion USD20.92 billion USD
ExchangeNasdaqCMNYSE
Listing DateJuly 16, 2021February 16, 1982
Security TypeCommon StockADR

Historical Performance

This chart compares the performance of RGC and TEVA by tracking the growth of an initial $10,000 investment in each. Use the tabs to select the desired time period. Data is adjusted for dividends and splits.

RGC vs. TEVA: Growth of a $10,000 investment over the past one year.

Historical Performance at a Glance

SymbolRGCTEVA
5-Day Price Return-7.08%1.08%
13-Week Price Return20.60%0.07%
26-Week Price Return12,370.00%1.60%
52-Week Price Return5,568.18%-11.57%
Month-to-Date Return-5.53%6.92%
Year-to-Date Return9,492.31%-26.16%
10-Day Avg. Volume0.26M2.65M
3-Month Avg. Volume2.29M2.25M
3-Month Volatility644.75%23.35%
Beta2.37-0.27

Profitability

Return on Equity (TTM)

RGC

-54.75%

Pharmaceuticals Industry

Max
38.59%
Q3
19.84%
Median
11.90%
Q1
5.63%
Min
-9.96%

RGC has a negative Return on Equity of -54.75%. This indicates the company is generating a loss for its shareholders, which can be a result of unprofitability or negative shareholder equity and is often a sign of financial distress.

TEVA

-2.58%

Pharmaceuticals Industry

Max
38.59%
Q3
19.84%
Median
11.90%
Q1
5.63%
Min
-9.96%

TEVA has a negative Return on Equity of -2.58%. This indicates the company is generating a loss for its shareholders, which can be a result of unprofitability or negative shareholder equity and is often a sign of financial distress.

RGC vs. TEVA: A comparison of their Return on Equity (TTM) against the Pharmaceuticals industry benchmark.

Net Profit Margin (TTM)

RGC

--

Pharmaceuticals Industry

Max
34.51%
Q3
17.73%
Median
12.12%
Q1
5.99%
Min
-7.73%

Net Profit Margin data for RGC is currently unavailable.

TEVA

-0.95%

Pharmaceuticals Industry

Max
34.51%
Q3
17.73%
Median
12.12%
Q1
5.99%
Min
-7.73%

TEVA has a negative Net Profit Margin of -0.95%, indicating the company is operating at a net loss as its expenses exceeded its revenues.

RGC vs. TEVA: A comparison of their Net Profit Margin (TTM) against the Pharmaceuticals industry benchmark.

Operating Profit Margin (TTM)

RGC

--

Pharmaceuticals Industry

Max
41.53%
Q3
23.00%
Median
16.24%
Q1
9.24%
Min
-6.94%

Operating Profit Margin data for RGC is currently unavailable.

TEVA

5.38%

Pharmaceuticals Industry

Max
41.53%
Q3
23.00%
Median
16.24%
Q1
9.24%
Min
-6.94%

TEVA’s Operating Profit Margin of 5.38% is in the lower quartile for the Pharmaceuticals industry. This indicates weaker profitability from core operations, which may stem from inefficiencies or competitive pressures on pricing.

RGC vs. TEVA: A comparison of their Operating Profit Margin (TTM) against the Pharmaceuticals industry benchmark.

Profitability at a Glance

SymbolRGCTEVA
Return on Equity (TTM)-54.75%-2.58%
Return on Assets (TTM)-51.38%-0.40%
Net Profit Margin (TTM)---0.95%
Operating Profit Margin (TTM)--5.38%
Gross Profit Margin (TTM)--50.88%

Financial Strength

Current Ratio (MRQ)

RGC

42.68

Pharmaceuticals Industry

Max
4.49
Q3
2.77
Median
1.74
Q1
1.26
Min
0.11

RGC’s Current Ratio of 42.68 is exceptionally high, placing it well outside the typical range for the Pharmaceuticals industry. This indicates a very strong liquidity position, though such a high ratio may also suggest that the company is not using its assets efficiently to generate profits.

TEVA

1.06

Pharmaceuticals Industry

Max
4.49
Q3
2.77
Median
1.74
Q1
1.26
Min
0.11

TEVA’s Current Ratio of 1.06 falls into the lower quartile for the Pharmaceuticals industry. This indicates a tighter liquidity situation and a more constrained capacity to handle short-term debt than many of its competitors.

RGC vs. TEVA: A comparison of their Current Ratio (MRQ) against the Pharmaceuticals industry benchmark.

Debt-to-Equity Ratio (MRQ)

RGC

0.00

Pharmaceuticals Industry

Max
2.44
Q3
1.07
Median
0.42
Q1
0.11
Min
0.00

Falling into the lower quartile for the Pharmaceuticals industry, RGC’s Debt-to-Equity Ratio of 0.00 points to a conservative financing strategy. This results in lower financial risk but potentially limits strategic investments compared to more leveraged competitors.

TEVA

2.52

Pharmaceuticals Industry

Max
2.44
Q3
1.07
Median
0.42
Q1
0.11
Min
0.00

With a Debt-to-Equity Ratio of 2.52, TEVA operates with exceptionally high leverage compared to the Pharmaceuticals industry norm. This suggests an aggressive reliance on debt financing, which can magnify returns but also significantly elevates financial risk.

RGC vs. TEVA: A comparison of their Debt-to-Equity Ratio (MRQ) against the Pharmaceuticals industry benchmark.

Interest Coverage Ratio (TTM)

RGC

--

Pharmaceuticals Industry

Max
103.95
Q3
44.18
Median
9.83
Q1
2.82
Min
-42.71

Interest Coverage Ratio data for RGC is currently unavailable.

TEVA

-0.38

Pharmaceuticals Industry

Max
103.95
Q3
44.18
Median
9.83
Q1
2.82
Min
-42.71

TEVA has a negative Interest Coverage Ratio of -0.38. This indicates that its earnings were insufficient to cover even its operational costs, let alone its interest payments, signaling significant financial distress.

RGC vs. TEVA: A comparison of their Interest Coverage Ratio (TTM) against the Pharmaceuticals industry benchmark.

Financial Strength at a Glance

SymbolRGCTEVA
Current Ratio (MRQ)42.681.06
Quick Ratio (MRQ)41.890.68
Debt-to-Equity Ratio (MRQ)0.002.52
Interest Coverage Ratio (TTM)---0.38

Growth

Revenue Growth

RGC vs. TEVA: A side-by-side comparison of their Revenue Growth for the MRQ (YoY), TTM (YoY), 3-Year CAGR, and 5-Year CAGR periods.

EPS Growth

RGC vs. TEVA: A side-by-side comparison of their EPS Growth for the MRQ (YoY), TTM (YoY), 3-Year CAGR, and 5-Year CAGR periods.

Dividend

Dividend Yield (TTM)

RGC

0.00%

Pharmaceuticals Industry

Max
6.98%
Q3
3.32%
Median
2.13%
Q1
0.14%
Min
0.00%

RGC currently does not pay a dividend, resulting in a yield of 0%. This is a common strategy for growth-focused companies that prioritize reinvesting earnings, though it may be less typical in mature, income-oriented sectors.

TEVA

0.00%

Pharmaceuticals Industry

Max
6.98%
Q3
3.32%
Median
2.13%
Q1
0.14%
Min
0.00%

TEVA currently does not pay a dividend, resulting in a yield of 0%. This is a common strategy for growth-focused companies that prioritize reinvesting earnings, though it may be less typical in mature, income-oriented sectors.

RGC vs. TEVA: A comparison of their Dividend Yield (TTM) against the Pharmaceuticals industry benchmark.

Dividend Payout Ratio (TTM)

RGC

0.00%

Pharmaceuticals Industry

Max
165.20%
Q3
90.59%
Median
49.13%
Q1
28.91%
Min
0.00%

RGC has a Dividend Payout Ratio of 0%, indicating it does not currently pay a dividend. This is a common strategy for growth-oriented companies that reinvest all profits back into the business.

TEVA

0.00%

Pharmaceuticals Industry

Max
165.20%
Q3
90.59%
Median
49.13%
Q1
28.91%
Min
0.00%

TEVA has a Dividend Payout Ratio of 0%, indicating it does not currently pay a dividend. This is a common strategy for growth-oriented companies that reinvest all profits back into the business.

RGC vs. TEVA: A comparison of their Dividend Payout Ratio (TTM) against the Pharmaceuticals industry benchmark.

Dividend at a Glance

SymbolRGCTEVA
Dividend Yield (TTM)0.00%0.00%
Dividend Payout Ratio (TTM)0.00%0.00%

Valuation

Price-to-Earnings Ratio (TTM)

RGC

--

Pharmaceuticals Industry

Max
42.51
Q3
26.88
Median
19.11
Q1
15.12
Min
0.00

P/E Ratio data for RGC is currently unavailable.

TEVA

--

Pharmaceuticals Industry

Max
42.51
Q3
26.88
Median
19.11
Q1
15.12
Min
0.00

P/E Ratio data for TEVA is currently unavailable.

RGC vs. TEVA: A comparison of their Price-to-Earnings Ratio (TTM) against the Pharmaceuticals industry benchmark.

Price-to-Sales Ratio (TTM)

RGC

--

Pharmaceuticals Industry

Max
7.55
Q3
4.54
Median
2.11
Q1
1.52
Min
0.00

P/S Ratio data for RGC is currently unavailable.

TEVA

1.25

Pharmaceuticals Industry

Max
7.55
Q3
4.54
Median
2.11
Q1
1.52
Min
0.00

In the lower quartile for the Pharmaceuticals industry, TEVA’s P/S Ratio of 1.25 indicates its revenue is valued more conservatively than most of its peers. This could present a compelling opportunity if the market has overlooked its sales-generating capabilities.

RGC vs. TEVA: A comparison of their Price-to-Sales Ratio (TTM) against the Pharmaceuticals industry benchmark.

Price-to-Book Ratio (MRQ)

RGC

9.57

Pharmaceuticals Industry

Max
9.78
Q3
4.96
Median
2.23
Q1
1.46
Min
0.60

RGC’s P/B Ratio of 9.57 is in the upper tier for the Pharmaceuticals industry. This indicates that investors are paying a premium relative to the company’s net assets, a valuation that hinges on its ability to generate superior profits.

TEVA

2.80

Pharmaceuticals Industry

Max
9.78
Q3
4.96
Median
2.23
Q1
1.46
Min
0.60

TEVA’s P/B Ratio of 2.80 is within the conventional range for the Pharmaceuticals industry. This shows a balanced market view, where the stock’s price is neither at a significant premium nor a discount to the book value of its peers.

RGC vs. TEVA: A comparison of their Price-to-Book Ratio (MRQ) against the Pharmaceuticals industry benchmark.

Valuation at a Glance

SymbolRGCTEVA
Price-to-Earnings Ratio (TTM)----
Price-to-Sales Ratio (TTM)--1.25
Price-to-Book Ratio (MRQ)9.572.80
Price-to-Free Cash Flow Ratio (TTM)--18.48